HomeMedicine
Medicine
More than two-thirds of people with atopic dermatitis and skin of color experienced skin improvement in a first-of-its-kind lebrikizumab study
INDIANAPOLIS, March 10, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced results from a first-of-its-kind study of lebrikizumab specifically designed for people with skin of color and moderate-to-severe atopic dermatitis, commonly called eczema. In this study, treatment with lebrikizumab, an investigational medicine, showed improvement...
Ascletis Announces Poster Presentation of Phase II Study Final Results of FASN Inhibitor ASC40 for Treatment of Acne at 2024 AAD Annual Meeting
HANGZHOU and SHAOXING, China, March 10, 2024 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces the poster presentation of Phase II study final results of ASC40, a first-in-class fatty acid synthase (FASN) inhibitor for treatment of acne, at the 2024 American Academy...
APPIS 2024: Healthcare Stakeholders Come Together to Prioritize Action for Better Patient Outcomes in Asia Pacific, Middle East, and Africa USA – English Indonesia – Bahasa APAC...
Since 2021, the APPIS platform has brought together over 2,000 people from more than 65 countries to address barriers to healthcare access.
Over 40 healthcare expert speakers will cover critical topics from health literacy, health policy shaping and future readiness at the APPIS Summit 2024.
The...
Health and Wellness Market size to increase by USD 1,661.81 billion between 2022 to 2027, Beauty and Personal Care Products to be the major...
NEW YORK, March 10, 2024 /PRNewswire/ -- The health and wellness market size is expected to grow by USD 1,661.81 billion from 2022 to 2027, according to Technavio. In addition, the growth momentum of the market will progress at a CAGR of 6.49% during the...
RemeGen Presents Oral Presentation on Evaluation of Its Proprietary Disitamab Vedotin (RC48) for Cervical Cancer at ESGO 2024 USA – English APAC – English
YANTAI, China, March 10, 2024 /PRNewswire/ -- RemeGen Co. Ltd.("RemeGen" or "the Company") (9995.HK, 688331.SH), a commercial-stage biotechnology company, recently gave an oral presentation on an interim analysis of the evaluation of the Company's proprietary Disitamab Vedotin (RC48), an investigational anti-HER2 antibody-drug conjugate (ADC)...
Billion-dollar Family Office Announces $20 Million USD Investment in Pioneering Web3 Wellness Venture Live4Well USA – English APAC – English India – English
HONG KONG, March 11, 2024 /PRNewswire/ -- In a strategic move that underscores a commitment to innovative market strategies, a billion- dollar family office led by Miranda Wong has announced a substantial $20 million USD investment in the promising Web3 wellness initiative, Live4Well. This...